Filament Gets Approval For Phase 2 Trial of Psilocybin Drug For Depression

Filament Health Announces Second Quarter 2024 Financial Results And Operational Highlights

Filament Health Announces Major Intellectual Property Expansion

Filament Health Announces Closing of Warrant Exercise, Note Conversion And Concurrent Private Placement Of Common Shares